When it comes to life-saving treatments for our beloved pets, the age-old adage, "You get what you pay for," often rings true. However, at World Paws, we pride ourselves on being an exception to this rule. Our high-quality GS-441524 is not only affordable but also accessible to those who need it most.

Our Mission

As a team of animal advocates with over 25 years of experience, we understand the emotional and financial strain that comes with treating FIP (Feline Infectious Peritonitis). Many of us are FIP parents ourselves, having faced the challenge of exorbitant treatment costs to save our own cats. This personal experience drives our commitment to make high-quality treatments accessible to all pet owners.

Why Our GS-441524 is Affordable

Producing high-quality GS-441524 is not inherently expensive. At World Paws, we have chosen to maintain lower profit margins to ensure that our prices remain affordable. Our goal is not to maximize profits but to provide an effective and accessible solution for treating FIP. By doing so, we aim to support the FIP community and save as many cats as possible from euthanasia due to prohibitive costs or the necessity of using low-quality products.

Our Commitment to Quality

Veterinary fees are already a significant challenge for most pet parents. By offering high-quality GS at lower prices, we hope to alleviate some of the financial burdens on pet owners. Additionally, to support the healing process and reduce any extra costs associated with treatment, we include Bloom Bioscience supplements with every first order. These supplements, provided by our sponsor Bloom Bioscience, are designed to speed up the healing process and ensure the best possible outcome for your cat.

Join Us in Making a Difference

We invite you to join us in our mission to make a real difference in the lives of cats suffering from FIP. Together, we can provide affordable, high-quality treatments and give these cats the best chance at a full recovery.

If you have any questions or need more information, please don't hesitate to reach out. Thank you for supporting World Paws and our efforts to save lives.

Harmony Vet Team, DVM PhD Oct 1, 2024

Introduction

Feline Infectious Peritonitis (FIP) was first described in 1963 (1) and was considered fatal to cats until 2019 when Dr. Pedersen and his team at the University of California, Davis, published the first successful treatment using GS-441524, a molecule with antiviral properties (2). This initial treatment involved administering injections over 84 days. However, the injectable form of GS-441524 is stable only in a very acidic solution (pH 1.5 - 2), making the injections painful and causing skin sores and fibrosis over time. Consequently, suppliers developed oral formulations, such as tablets and capsules, to alleviate these issues.

Concerns and Comparative Efficacy

Oral administration of medications often raises concerns about efficiency compared to injections due to the involvement of the gastrointestinal tract, which can affect drug absorption. In both human and veterinary medicine, oral dosages are typically adjusted to account for partial absorption. For instance, the anti-nausea medication Cerenia is administered at 1 mg/kg when injected but requires 2 mg/kg when given orally.

The efficacy of oral GS-441524 was first demonstrated when cats transitioned from a month of injections to an adjusted oral dosage. The first scientific article documenting successful treatment using only oral tablets was published in 2021 (3). Since then, thousands of cats have been successfully treated and cured with oral GS-441524, with multiple studies confirming these results (4, 5, 6). Cats diagnosed with FIP can now start treatment with oral forms (tablets or capsules) and achieve the same success rates as those treated with injections.

Advantages of Oral Treatment

Oral treatment is often preferred over injections due to ease of administration, which ensures compliance and adherence to the treatment regimen. Proper adherence is crucial for the success of FIP treatment. Currently, a cat treated at the appropriate dose with the necessary supportive care has an above 85% chance of being cured.

Exceptions to Oral Treatment

In less than 5% of cases, oral treatment may not be suitable for all cats. Exceptions include:

1. Cats in critical condition requiring hospitalization and unable to swallow.

2. Cats that consistently vomit or have uncontrollable diarrhea.

3. Rare cases where cats do not absorb the oral form correctly. This should be considered if a cat does not respond to treatment despite dosage adjustments.

However, most cats can transition from injections to oral treatment after one to four weeks of initial therapy, provided the exceptions listed above improve with the injections.

Conclusion

More than 95% of cats respond well to only oral GS-441524 treatment for FIP (starting on oral treatment from day 1), provided the treatment regimen is rigorously followed. Oral treatment is as efficient as injections for Feline Infectious Peritonitis, offering a less painful and more manageable alternative for cat owners and veterinarians.

References

1. Pedersen, N. C. (2009). A review of feline infectious peritonitis virus infection: 1963–2008. Journal of Feline Medicine and Surgery, 11(4), 225-258.

2. Pedersen, N. C., Perron, M., Bannasch, M., Montgomery, E., Murakami, E., Liepnieks, M., & Liu, H. (2019). Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. Journal of Feline Medicine and Surgery, 21(4), 271-281.

3. Krentz, D., Zenger, K., Alberer, M., Felten, S., Bergmann, M., Dorsch, R., ... & Hartmann, K. (2021). Curing cats with feline infectious peritonitis with an oral multi-component drug containing GS-441524. Viruses, 13(11), 2228.

4. Zwicklbauer, K., Krentz, D., Bergmann, M., Felten, S., Dorsch, R., Fischer, A., ... & Hartmann, K. (2023). Long-term follow-up of cats in complete remission after treatment of feline infectious peritonitis with oral GS-441524.Journal of Feline Medicine and Surgery, 25(8), 1098612X231183250.

5. Katayama, M., & Uemura, Y. (2023). Prognostic prediction for therapeutic effects of Mutian on 324 client-owned cats with feline infectious peritonitis based on clinical laboratory indicators and physical signs. Veterinary Sciences, 10(2), 136.

6. Cosaro, E., Pires, J., Castillo, D., Murphy, B. G., & Reagan, K. L. (2023). Efficacy of oral remdesivir compared to GS-441524 for treatment of cats with naturally occurring effusive feline infectious peritonitis: a blinded, non- inferiority study. Viruses, 15(8), 1680.